文献速递甲状腺核医学肿瘤 PET/CT

[18F]四氟硼酸盐PET/CT与[124I]碘PET/CT用于甲状腺癌显像的初步临床研究

Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer.
PubMed 文献 · Clin Nucl Med · 2018-01-01

本初步研究纳入9例新诊断的分化型甲状腺癌全切术后患者,同时行[18F]TFB与[124I]NaI PET/CT,按患者和病灶分析甲状腺残留组织及转移灶;[18F]TFB在检测甲状腺癌及其转移方面不劣于[124I]NaI,并能检出[124I]NaI阴性的活性转移灶。

要点

  • 9例患者[18F]TFB与[124I]NaI PET/CT均为阳性。
  • 病灶分析[18F]TFB检出41个病灶,[124I]NaI检出40个。
  • [18F]TFB检出2例[124I]NaI阴性颈部淋巴结转移。

核心结论

  • 本初步研究显示[18F]TFB-PET在检测甲状腺癌及其转移方面不劣于[124I]NaI-PET,并能检出[124I]NaI-PET阴性的活性分化型甲状腺癌转移灶。

研究设计与样本

  • 初步研究纳入9例新诊断的分化型甲状腺癌患者,均在全甲状腺切除术后行[18F]TFB与[124I]NaI PET/CT,并按患者和病灶进行视觉分析及半定量分析。

主要发现

  • 所有患者[18F]TFB与[124I]NaI PET/CT扫描均为阳性。
  • 甲状腺残留组织对碘的滞留显著高于[18F]TFB(P < 0.01)。
  • 病灶分析中[18F]TFB共检出41个病灶,[124I]NaI共检出40个病灶。
  • 9例患者中6例两种放射性药物检出的病灶数目完全相同。
  • 1例患者中[18F]TFB-PET/CT漏诊2个[124I]NaI阳性的良性甲状腺残留;另1例两种示踪剂检出颈部不同甲状腺残留组织。

临床怎么用

  • 作者认为,进一步临床评估[18F]TFB作为PET示踪剂用于甲状腺病理生理及表达人钠/碘同向转运体的肿瘤显像高度必要。

局限性

  • 原文为初步研究,样本量为9例。
  • 原文结论指出进一步临床评估高度必要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Recently, [F]tetrafluoroborate ([F]TFB) has been introduced as a versatile PET probe for imaging the human sodium/iodide symporter activity. This pilot study aimed to compare [F]TFB-PET/CT with [I]NaI-PET/CT imaging in thyroid cancer patients. METHODS: Nine patients with newly diagnosed differentiated thyroid cancer underwent both [F]TFB- and [I]NaI-PET/CT after total thyroidectomy. PET/CT scans were visually analyzed for the presence of remnant thyroid tissue and for metastatic lesions on a patient and lesion basis. For semiquantitative analysis, thyroid remnant/tumor to blood pool ratios were calculated. RESULTS: All patients presented with positive [F]TFB and [I]NaI-PET/CT scans. Retention of I in remnant thyroid tissue was significantly higher as compared with [F]TFB (P < 0.01). In a lesion-based analysis, both tracers identified an almost equal number of foci with [F]TFB depicting a total of 41 foci and I a total of 40 foci, respectively. In 6 of 9 patients, both radiopharmaceuticals returned an identical number of foci. Two I-positive benign thyroid remnants were missed by [F]TFB-PET/CT in a single patient. In another case, both tracers identified different thyroid remnant tissues in the cervical region. Notably, [F]TFB demonstrated additional (I-negative) cervical lymph node metastases in 2 patients, leading to an overall agreement between the radiotracers of 91% (74/81 foci). DISCUSSION: In this pilot study, [F]TFB-PET was not inferior to [I]NaI-PET for detecting thyroid cancer and its metastases and was able to detect [I]NaI-PET-negative viable differentiated thyroid cancer metastases. Further clinical evaluation as a PET tracer for imaging thyroid pathophysiology and human sodium/iodide symporter expressing neoplasms is highly warranted.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Samnick S, Al-Momani E, Schmid JS, et al. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer. Clin Nucl Med. 2018. PMID: 29356744. doi:10.1097/RLU.0000000000001977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。